 |
|
Telomerase reverse transcriptase promoter mutation and its clinical implication in thyroid cancer
Jae Hoon Chung
Precis Future Med. 2018;2(1):8-17. Published online 2018 Mar 30 DOI: https://doi.org/10.23838/pfm.2018.00016
|
|
Citations to this article as recorded by
 Advances in Molecular Profiling and Their Potential Influence on the Extent of Surgery in Well-Differentiated Thyroid Carcinoma (WDTC)
Constantinos Parpounas, Vasilis Constantinides
Life.2023; 13(6): 1382. CrossRef The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis
Bojie Chen, Yuan Shi, Yanan Xu, Jing Zhang
Clinical Endocrinology.2021; 94(5): 731. CrossRef Risk Stratification Using a Novel Genetic Classifier IncludingPLEKHS1Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
Thyroid.2020; 30(11): 1589. CrossRef BRAF and TERT promoter mutations: clinical application in thyroid cancer
Jae Hoon Chung
Endocrine Journal.2020; 67(6): 577. CrossRef
|